» Articles » PMID: 28600498

Deregulation of MiRNAs in Malignant Pleural Mesothelioma is Associated with Prognosis and Suggests an Alteration of Cell Metabolism

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive human cancer and miRNAs can play a key role for this disease. In order to broaden the knowledge in this field, the miRNA expression was investigated in a large series of MPM to discover new pathways helpful in diagnosis, prognosis and therapy. We employed nanoString nCounter system for miRNA profiling on 105 MPM samples and 10 healthy pleura. The analysis was followed by the validation of the most significantly deregulated miRNAs by RT-qPCR in an independent sample set. We identified 63 miRNAs deregulated in a statistically significant way. MiR-185, miR-197, and miR-299 were confirmed differentially expressed, after validation study. In addition, the results of the microarray analysis corroborated previous findings concerning miR-15b-5p, miR-126-3p, and miR-145-5p. Kaplan-Meier curves were used to explore the association between miRNA expression and overall survival (OS) and identified a 2-miRNA prognostic signature (Let-7c-5p and miR-151a-5p) related to hypoxia and energy metabolism respectively. In silico analyses with DIANA-microT-CDS highlighted 5 putative targets in common between two miRNAs. With the present work we showed that the pattern of miRNAs expression is highly deregulated in MPM and that a 2-miRNA signature can be a new useful tool for prognosis in MPM.

Citing Articles

Pleural mesothelioma (PMe): The evolving molecular knowledge of a rare and aggressive cancer.

Rigon M, Mutti L, Campanella M Mol Oncol. 2024; 18(4):797-814.

PMID: 38459714 PMC: 10994233. DOI: 10.1002/1878-0261.13591.


ATG5 as biomarker for early detection of malignant mesothelioma.

Tomasetti M, Monaco F, Strogovets O, Volpini L, Valentino M, Amati M BMC Res Notes. 2023; 16(1):61.

PMID: 37095543 PMC: 10127310. DOI: 10.1186/s13104-023-06330-1.


The Genes-Stemness-Secretome Interplay in Malignant Pleural Mesothelioma: Molecular Dynamics and Clinical Hints.

Stella G, Marchio C, Bari E, Ferrarotti I, Bertuccio F, Di Gennaro A Int J Mol Sci. 2023; 24(4).

PMID: 36834912 PMC: 9963101. DOI: 10.3390/ijms24043496.


Define the Two Molecular Subtypes of Epithelioid Malignant Pleural Mesothelioma.

Saddozai U, Wang F, Khattak S, Akbar M, Badar M, Khan N Cells. 2022; 11(18).

PMID: 36139498 PMC: 9497219. DOI: 10.3390/cells11182924.


Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects.

Kuryk L, Rodella G, Staniszewska M, Pancer K, Wieczorek M, Salmaso S Front Oncol. 2022; 12:916839.

PMID: 35785199 PMC: 9247278. DOI: 10.3389/fonc.2022.916839.


References
1.
Li S, Ma Y, Hou X, Liu Y, Li K, Xu S . MiR-185 acts as a tumor suppressor by targeting AKT1 in non-small cell lung cancer cells. Int J Clin Exp Pathol. 2015; 8(9):11854-62. PMC: 4637756. View

2.
Rogers S, Girolami M, Kolch W, Waters K, Liu T, Thrall B . Investigating the correspondence between transcriptomic and proteomic expression profiles using coupled cluster models. Bioinformatics. 2008; 24(24):2894-900. PMC: 4141638. DOI: 10.1093/bioinformatics/btn553. View

3.
Wang C, Yuan P, Li Y . MiR-126 regulated breast cancer cell invasion by targeting ADAM9. Int J Clin Exp Pathol. 2015; 8(6):6547-53. PMC: 4525868. View

4.
Crispi S, Calogero R, Santini M, Mellone P, Vincenzi B, Citro G . Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target. PLoS One. 2009; 4(9):e7016. PMC: 2737627. DOI: 10.1371/journal.pone.0007016. View

5.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D . Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016; 387(10026):1405-1414. DOI: 10.1016/S0140-6736(15)01238-6. View